Short-term and long-term effects of tibolone in postmenopausal women

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 10, 2016, Pages

  Formoso, Giulio ^a   Perrone, Enrica ^b   Maltoni, Susanna ^c   Balduzzi, Sara ^d   Wilkinson, Jack ^e   Basevi, Vittorio ^f   Marata, Anna Maria ^a   Magrini, Nicola ^g   D'Amico, Roberto ^d   Bassi, Chiara ^h   Maestri, Emilio ⁱ  

^a Health and Social Policies Dir   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Agenzia Sanitaria e Sociale Regionale Emilia Romagna   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f Emilia Romagna Health and Welfare Directorate   (Italy)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

^h S MARIA NUOVA HOSPITAL   (Italy)

ⁱ Regional Agency for Health and Social Care   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; DIENOGEST; ESTRADIOL; ESTRADIOL VALERATE; ESTRIOL; ESTROGEN; MEDROGESTONE; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTREL; PLACEBO; TIBOLONE; PREGNANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BLEEDING; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLIMACTERIUM; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; GYNECOLOGIC DISEASE; HORMONAL THERAPY; HUMAN; INSOMNIA; MENOPAUSAL SYNDROME; PAINFUL SEXUAL INTERCOURSE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THERAPY EFFECT; URINARY TRACT INFECTION; VAGINAL DRYNESS; VAGINITIS; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; AGED; BREAST NEOPLASMS; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; DRUG EFFECTS; DYSPAREUNIA; ESTROGEN THERAPY; FEMALE; HOT FLASHES; META ANALYSIS; MIDDLE AGED; PROCEDURES; SWEATING; TUMOR RECURRENCE; UTERUS BLEEDING;

AGED; BREAST NEOPLASMS; DYSPAREUNIA; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NORPREGNENES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; SWEATING; UTERINE HEMORRHAGE;

EID: 84991210701     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008536.pub3     Document Type: Review

References (104)

1. Al-Azzawi F, Wahab M, Habiba M, Akkad A, Mason T. Continuous combined hormone replacement therapy compared with tibolone. Obstetrics and Gynecology 1999;93(2):258-64.
2. Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, et al. Endometrial effects of tibolone. Journal of Clinical Endocrinology and Metabolism 2007;99(3):911-8.
3. Baracat EC, Barbosa IC, Giordano MG, Haidar MA, Marinho RM, Menegocci JC, et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 2002;5:60-9.
4. Benedek-Jaszmann LJ. Long-term placebo-controlled efficacy and safety study of ORG OD 14 in climacteric women. Maturitas 1987;Suppl 1:25-33.
5. Berning B, van Kuijk C, Coelingh Bennink HJT, Fauser BCJ. Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women. Maturitas 2000;35:81-8.
6. Bouchard P, Panay N, de Villiers TJ, Vincendon P, Bao W, Cheng RJ, et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric 2012;15:12-20.
7. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, et al. LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. New England Journal of Medicine 2008;359(7):697-708.
8. Ettinger B, Kenemans P, Johnson SR, Mol-Arts M, Van Os S, Seifert W, et al. Endometrial effects of tibolone in elderly, osteoporotic women. Obstetrics and Gynaecology 2008;112:653-9.
9. de Aloysio D, Altieri P, Penacchioni P, Salgarello M, Ventura V. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT. Maturitas 1998;29:261-4.
10. Dören M, Rübig A, Coelingh Bennink HJ, Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999;6:299-306.
11. Egarter C, Huber J, Leikermoser R, Haidbauer R, Pusch H, Fischl F, et al. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 1996;23(1):55-62.
12. Elfituri A, Sherif F, Elmahaishi M, Chrystyn H. Two hormone replacement therapy (HRT) regimens for middle-eastern postmenopausal women. Maturitas 2005;52:52-9.
13. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. Journal of Clinical Endocrinology and Metabolism 2001;86(10):4717-26.
14. Gupta B, Mittal P, Khuteta R, Bhargava A. A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynaecology India 2013;63:194-8.
15. Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. British Journal of Obstetrics and Gynaecology 1998;105(8):904-11.
16. Hammar ML, van de Weijer P, Franke HR, Pornel B, von Mauw EM, Nijland EA, TOTAL Study Investigators Group. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG 2007;114(12):1522-9.
17. Hänggi W, Bersinger N, Altermatt HJ, Birkhäuser MH. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRTusers. Maturitas 1997;27(2):133-43.
18. Huber J, Palacios S, Berglund L, Hänggi W, Sathanandan SM, Christau S, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 2002;109(8):886-93.
19. Hudita D, Posea C, Ceausu I, Rusu M. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women. European Review for Medical and Pharmacological Sciences 2003;7(5):117-25.
20. Jacobsen DE, Melis RJ, Verhaar HJ, Olde Rikkert MG. Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial. Journal of the American Medical Directors Association 2012;13:189.e1-7.
21. Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, et al. Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Research 2012;14:R13.
22. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, et al. LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncology 2009;10(2):135-46.
23. Sismondi P, Kimmig R, Kubista E, et al. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients - data from LIBERATE trial. Maturitas 2011;70(4):365-72.
24. Kökçü A, Çetinkaya MB, Yanik F, Alper T, Malatyalioğlu E. The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas 2000;36:75-80.
25. Kroiss R, Fentiman IS, Helmond FA, Rymer J, Foidart JM, Bundred N, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. BJOG 2005;112(2):228-33.
26. Kubista E, Planellas Gomez JVM, Dowsett M, Foidart JM, Pohlodek K, Serreyn R, et al. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial. Clinical Cancer Research 2007;13(14):4185-90.
27. Landgren MB, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 2002;109(10):1109-14.
28. Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas 2005;14:222-30.
29. Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, et al. OPAL Investigators. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. European Heart Journal 2006;27:746-55.
30. Langer RD, Landgren BM, Rymer J, Helmond FA, OPAL Investigators. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. American Journal of Obstetrics and Gynecology 2006;195(5):1320-7.
31. Meeuwsen IB, Samson MM, Duursma SA, Verhaar HJ. The influence of tibolone on quality of life in postmenopausal women. Maturitas 2002;41(1):35-43.
32. Mendoza N, Suárez AM, Álamo F, Bartual E, Vergara F, Herruzo A. Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17β-estradiol for hormonal replacement therapy in women with surgical menopause. Maturitas 2000;37(1):37-43.
33. Mendoza N, Pisón JA, Fernández M, Sánchez MC, Malde J, Miranda JA. Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus. Maturitas 2002;41:289-98.
34. Morais-Socorro M, Cavalcanti MA, Martins R, Neto Francisco P, Rezende A, Azevedo G, et al. Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial. Gynecologic Endocrinology 2012;28:483-7.
35. Nappi RE, Sances G, Sommacal A, Detaddei S, Facchinetti F, Cristina S, et al. Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. Menopause 2006;13(5):818-25.
36. Nathorst-Böös J, Hammar M. Effect on sexual life - a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997;26(1):15-20.
37. Nijland EA, Nathorst-Boos J, Palacios S, van de Weijer PW, Davis S, Stathopoulos VM, et al. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. Climateric 2009;12:114-21.
38. Okon MA, Lee S, Laird SM, Li TC. A prospective randomized controlled study comparing the morphological and biochemical responses of the endometrium to two different forms of 'period-free' hormone replacement therapy. Human Reproduction 1998;13(8):2261-5.
39. Osmanağaoğlu MA, Atasaral T, Baltaci D, Bozkaya H. Effect of different preparations of hormone therapy on sexual dysfunction in naturally postmenopausal women. Climacteric 2006;9:464-72.
40. Polisseni AF, Andrade AT, Ribeiro LC, Castro IQ, Brandão M, Polisseni F, et al. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study. Maturitas 2013;74:172-8.
41. Ross LA, Alder EM, Cawood EHH, Brown J, Gebbie AE. Psychological effects of hormone replacement therapy: a comparison of tibolone and a sequential estrogen therapy. Journal of Psychosomatic Obstetrics and Gynecology 1999;20:88-96.
42. Roux C, Pelissier C, Fechtenbaum J, Loiseau-Peres S, Benhamou CL. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporosis International 2002;13:241-8.
43. Siseles NO, Halperin H, Benencia HJ, Berg G, Pilnik S, Mesch V, et al. A comparative study of two hormone replacement therapy regimens on safety and efficacy variables. Maturitas 1995;21(3):201-10.
44. Swanson SG, Drosman S, Helmond FA, Stathopoulos VM. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006;13(6):917-25.
45. Uygur D, Yeşildaglar N, Erkaya S. Effect on sexual life - a comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate. Gynecologic Endocrinology 2005;20(4):209-12.
46. Vieira CS, Pereira FV, de Sá MFS, Paulo LJ, Martins WP, Ferriani RA. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study. Maturitas 2009;62:311-6.
47. Volpe A, Facchinetti F, Grasso A, Petraglia F, Campanini D, Genazzani AR. Benefits and risks of different hormonal replacement therapies in post-menopausal women. Maturitas 1986;8:327-34.
48. Wender MC, Edelweiss MI, Campos LS, de Castro JA, Spritzer PM. Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study. Menopause 2004;11:423-9.
49. Winkler UH, Altkemper R, Kwee B, Helmond FA, Coelingh Bennink HJT. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertility and Sterility 2000;74(1):10-9.
50. Wu MH, Pan HA, Wang ST, Hsu CC, Chang FM, Huang KE. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 2001;4(4):314-9.
51. Ziaei S, Masoumi R, Faghihzadeh S. Comparing the effects of continuous hormone replacement therapy and tibolone on the genital tract of menopausal women. A randomized controlled trial. Journal of Reproduction and Infertility 2010;11(3):183-7.
52. Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric 2010;13:147-56.
53. Argyroudis EM, Iatrakis G, Kourkoubas A, Georgoulias N, Kourounis G, Tsionis C, et al. Tibolone in the treatment of psychosomatic symptoms in menopause. Clinical and Experimental Obstetrics and Gynecology 1997;24(3):167-8.
54. Baksu A, Ayas B, Citak S, Kalan A, Baksu B, Goker N. Efficacy of tibolone and transdermal estrogen therapy on psychological symptoms in women following surgical menopause. International Journal of Gynaecology and Obstetrics 2005;91(1):58-62.
55. Beardsworth SA, Kearney CE, Purdie DW. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial. British Journal of Obstetrics and Gynaecology 1999;106(7):678-83.
56. Berlang C, Mendieta D, Alva G, del Carmen LM. Failure of tibolone to potentiate the pharmacological effect of fluoxetine in postmenopausal major depression. Journal of Women's Health 2003;12(1):33-9.
57. Bhattacharya SM. Tibolone versus conjugated oestrogen - what is the short-term treatment effect on health-related quality of life (HRQOL) in surgical menopausal women?. Journal of the Turkish-German Gynecology Association 2008;9(4):195-201.
58. Bhattacharya SM, Jha A. Effects of transdermal estradiol gel and oral tibolone on health-related quality of life after surgical menopause. International Journal of Gynaecology and Obstetrics 2010;110(3):213-6.
59. Bukulmez O, Al A, Gurdal H, Yarali H, Ulug B, Gurgan T. Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores: a prospective randomized trial. Fertility and Sterility 2001;75(4):737-43.
60. Cagnacci A, Baldassari F, Arangino S, Alessandrini C, Volpe A. Administration of tibolone decreases 24 h heart rate but not blood pressure of post-menopausal women. Maturitas 2004;48(2):155-60.
61. Cayan F, Dilek U, Pata O, Dilek S. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. Journal of Sexual Medicine 2008;5(1):132-8.
62. DeCensi A, Bonanni B, Maisonneuve P, Serrano D, Omodei U, Varricchio C, et al. A phase-III prevention trial of low dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Annals Oncology 2013;24:2753-60.
63. Fedele L, Bianchi S, Raffaelli R, Zanconato G. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. European Journal of Obstetric and Gynecological Reproductive Biology 2000;88(1):91-4.
64. Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, et al. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women. Gynecologic Endocrinology 2004;18(1):9-16.
65. Genazzani AR, Stomati M, Valentino V, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric 2011;14(6):661-8.
66. Inan I, Kelecki S, Yilmaz B. Psychological effects of tibolone and sequential estrogen-progestogen therapy in postmenopausal women. Gynecologic Endocrinology 2005;20(2):64-7.
67. Lundstrom E, Hirschberg AL, Soderqvist G. Digitized assessment of mammographic breast density - effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo. Maturitas 2011;70(4):361-4.
68. Nappi RE, Ferdeghini F, Sampaolo P, Vaccaro P, De Leonardis C, Albani F, et al. Clitoral circulation in postmenopausal women with sexual dysfunction: a pilot randomized study with hormone therapy. Maturitas 2006;55(3):288-95.
69. Onalan G, Onalan R, Selam B, Akar M, Gunenc Z, Topcuoglu A. Mood scores in relation to hormone replacement therapies during menopause: a prospective randomized trial. Tohoku Journal of Experimental Medicine 2005;207(3):223-31.
70. Palacios S, Menendez C, Jurado AR, Castaño R, Vargas JC. Changes in sex behaviour after menopause: effects of tibolone. Maturitas 1995;22(2):155-61.
71. Silva G, Lima S, Guazzelle R, Yamada S, Martins C. Hypoactive sexual desire disorder: tibolone and Tribulus terrestris are really effective?. Journal of Sexual Medicine 2015;12:30-1.
72. Simsek T, Karakus C, Trak B. Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period. Tibolone versus transdermal hormonal replacement system. Maturitas 2002;42:243-6.
73. Stefanos Z, Georgios I, Panagiotis P, Iordanis N, Panagiotis T, Georgios G, et al. Sequential tibolone versus progestin for premenopausal bleeding. Gineco (Ro) 2010;6:37-40.
74. Stevenson JC. Prevention of osteoporosis: one step forward, two steps back. Menopause International 2011;17(4):137-41.
75. Tasic L, Dunjic R, Vasiljevic M, Dikic S, Jurisic A, Tasic D. Comparison of two different types of hormone therapy effects on haemostatic parameters in early postmenopausal women. Srpski Arhiv za Celokupno Lekarstvo 2011;139(1-2):52-7.
76. Yuk JS, Yi KW, Kim T, Hur JY, Kim SH, Shin JH. Preliminary study: the body compositional change according to drospirenone (DRSP) containing lowdose hormone therapy and tibolone. Maturitas 2012;71:S46.
77. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289:454-65.
78. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
79. Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51.
80. Beral V. LIFT study is discontinued. BMJ (rapid response) 2006;332:667. http://www.bmj.com/content/332/7542/667.1/reply.
81. Beral V, Reeves G, Bull D, Green J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. Journal of the National Cancer Institute 2011;103:296-305.
82. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. New York: John Wiley & Sons, 2009.
83. Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, OPAL Investigators. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. European Heart Journal 2006;27:746-55.
84. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD001405.pub3]
85. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
86. Diggle P, Liang KY, Zeger SL. Longitudinal Data Analysis. New York: Oxford University Press, 1994.
87. Freedman RR, Norton D, Woodward S, Cornélissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. Journal of Clinical Endocrinology and Metabolism 1995;80(8):2354-8.
88. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
89. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration. www.cochrane-handbook.org. 2011.
90. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
91. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD002978.pub2]
92. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300:230-5.
93. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. Journal of Clinical Endocrinology and Metabolism 2002;87(1):16-23.
94. NCC-WCH National Collaborating Centre for Women's and Children's Health. Menopause. Commissioned by the National Institute for Health and Care Excellence. London: NCC-WCH, 2015.
95. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. Journal of General Internal Medicine 2008;23:1507-13.
96. Porter M, Penney GC, Russell D, Russell E, Templeton A. A population based survey of women's experience of the menopause. British Journal of Obstetrics and Gynaecology 1996;103(10):1025-8.
97. R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2015. [https://www.R-project.org/]
98. Gabriel Sanchez R, Sanchez Gomez LM, Carmona L, Roqué I Figuls M, Bonfill Cosp X. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002229.pub4]
99. Society of Obstetricians and Gynaecologist Canada. Managing menopause. Journal of Obstetrics and Gynaecology in Canada 2014;36 (9 e Suppl A):S1-S80.
100. Speroff L, Fritz MA. The Clinical Gynecologic Endocrinology and Infertility: The Cervical Spine Research Society Editorial Committee (Clinical Gynecologic Endocrinology and Infertility). Baltimore, MD: Lippincott Williams & Wilkins, 2004.
101. Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338:b2393.
102. Suckling J, Kennedy R, Lethaby A, Roberts H. Local oestrogen therapy for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD001500.pub2]
103. Viechtbauer W. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software 2010;36:1-48.
104. Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric 2010;13:147-56.